| 
 |
|
Dr. Christine Reynet is an enthusiastic and driven Professional with over 20 years experience in Drug Discovery, in both Biotech and Big Pharma, and in Research, particularly in Diabetes and related Metabolic Diseases. During her career, she has acquired extensive skills in management and leadership in cross-organisational and multi-cultural environments. She has a well demonstrated expertise in initiating, driving and delivering innovative projects, in designing and developing strategic plans, and also in the evaluation of a large variety of scientific licensing and business development opportunities.
Prior to co-founding McC+R&D Consulting Ltd as a pharmaceutical consultancy business, Christine was Senior Director and Head of Biology at (OSI)Prosidion, Oxford, UK. She was directly involved in the strategic direction of Discovery Research and was also leading a highly performing Biology Department. In addition, she was the internal chair of the Scientific Advisory Board. Christine joined (OSI)Pharmaceuticals Inc. in 2002 and was one of the founders of Prosidion Ltd. in 2003, a spin-out of OSIP, expanding and developing the Biology Dept and the Research organisation, focusing on the discovery and development of safer, more effective, innovative small molecules for the treatment of type 2 diabetes and obesity. During her 5 years at (OSI)Prosidion, Christine was a key player in the identification and progression of 4 novel compounds into development, including GPR119 agonist PSN821. She was also one of the main contributors to successful out-licensing.
Prior to Prosidion, Christine was Principal Scientist in Discovery Research at Novo Nordisk A/S, Denmark (1994-2002), where she ran a research group focusing on developing directly relevant model systems for studying the cellular mechanism of action of anti-diabetic drugs, and she initiated and/or developed several collaborations for novel exploratory projects targeting new therapies for type 2 diabetes. She was also Project Leader of external collaborations with Biotechs assessing novel technologies. In addition, she supported International Operations and Affiliates, and participated, as Management Committee Member and Danish Delegate, in European Commission programmes on "Insulin Resistance, Obesity and Type 2 Diabetes".
Before joining Novo Nordisk, Christine was a Harvard Medical Research Fellow in Dr. C. Ronald Kahn's laboratory at the Joslin Diabetes Center, Boston, USA (1991-1994).
Dr Reynet obtained her PhD in Molecular and Cellular Endocrinology in 1990 from Pierre and Marie Curie University, Paris, France, after her M.Sc. in Endocrinology and B.Sc. in Cellular Biology and Genetics. She has also published numerous articles, and regularly gives talks and seminars.
 |
